Alnylam Pharmaceuticals Inc (ALNY)
269.93
-3.98
(-1.45%)
USD |
NASDAQ |
Nov 04, 16:00
270.06
+0.13
(+0.05%)
After-Hours: 20:00
Alnylam Pharmaceuticals Research and Development Expense (Annual): 1.004B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.004B |
| December 31, 2022 | 883.02M |
| December 31, 2021 | 792.16M |
| December 31, 2020 | 654.82M |
| December 31, 2019 | 655.11M |
| December 31, 2018 | 505.42M |
| December 31, 2017 | 390.64M |
| December 31, 2016 | 382.39M |
| December 31, 2015 | 276.50M |
| December 31, 2014 | 190.25M |
| December 31, 2013 | 112.96M |
| Date | Value |
|---|---|
| December 31, 2012 | 86.57M |
| December 31, 2011 | 99.30M |
| December 31, 2010 | 106.38M |
| December 31, 2009 | 108.73M |
| December 31, 2008 | 96.88M |
| December 31, 2007 | 120.69M |
| December 31, 2006 | 49.80M |
| December 31, 2005 | 35.32M |
| December 31, 2004 | 24.60M |
| December 31, 2003 | 13.10M |
| December 31, 2002 | 3.342M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
654.82M
Minimum
2020
1.004B
Maximum
2023
797.90M
Average
792.16M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| BridgeBio Pharma Inc | 455.71M |
| Biomarin Pharmaceutical Inc | 746.77M |
| Johnson & Johnson | 15.08B |